Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8051-8060 Newer>

Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Pharmaceutical Executive November 1, 2011 Jeff Schindler	Prix Galien USA 2011 Hollywood has its Academy Awards and the pharmaceutical industry celebrates its brightest research accomplishments at the Prix Galien USA.
Pharmaceutical Executive November 1, 2011 Jeff Schindler	Fostering a Legacy of Leadership Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.
Pharmaceutical Executive November 1, 2011 Jill Wechsler	The Drug Shortages Struggle Clamor for critical therapies prompts probes of prices, production practices.
Pharmaceutical Executive November 1, 2011 Roger L. Williams	Spotlight on OTCs With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.
Pharmaceutical Executive November 1, 2011 Josef Bossart	Pharma Revolution Recalibrated Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
Pharmaceutical Executive November 1, 2011 Bill Drummy	Pharma's Visit to the Plastic Surgeon The bigger the company, the thicker the sclerosis, the more they need to suck out the fat.
Pharmaceutical Executive November 1, 2011	Europe Tackles 'Advertising in Disguise' Fears The EC's latest proposals have thrown water on Europe's fiery Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?
Pharmaceutical Executive November 1, 2011 Elizabeth O. Coulton	Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients.
Pharmaceutical Executive November 1, 2011 William Looney	R&D Costs: It's Industry's Problem If high prices that lower access are attributable to a flawed R&D model, can the pharmaceutical industry embrace delivering better results at lower costs.
<Older 8051-8060 Newer> Return to current articles.